The long list of new treatments reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics. New drugs for lung, breast, skin and blood cancers have made gains over standard of care, while other additions have expanded options for patients.
INCLUDED IN THIS TRENDLINE
With spotlight on FDA, Congress weighs reforms to accelerated drug approvals
FDA panel supports agency push to raise approval bar for certain cancer drugs
CAR-T treatment moves earlier as FDA widens approval of Gilead’s Yescarta
Yes, I'd like to sign up for the BioPharma Dive newsletter (optional). You can unsubscribe at any time. By completing this form, you accept the Terms of Use and Privacy Policy. You also agree to having your information shared with our sponsor, Advarra.
Please fill in form details to move ahead.
